The genetic architecture of type 2 diabetes pharmacotherapy: The emerging genomic evidence

Current Pharmaceutical Design

Volumn 20, Issue 22, 2014, Pages 3610-3619

  Kavvoura, F K ^a,b   Pappa, M ^c   Evangelou, E ^c   Ntzani, E E ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Diabetes; Pharmacogenomics; Systematic review; Therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; COLESEVELAM; CYTOCHROME P450 2C9; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; ORGANIC CATION TRANSPORTER 1; PIOGLITAZONE; POTASSIUM CHANNEL KCNQ1; REPAGLINIDE; SULFONYLUREA; SULFONYLUREA RECEPTOR 1; TOLAZAMIDE; TOLBUTAMIDE; TRANSCRIPTION FACTOR 7 LIKE 2; ANTIDIABETIC AGENT;

ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; EDEMA; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHARMACOGENOMICS; POSTPRANDIAL STATE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; DIABETES MELLITUS, TYPE 2; GENETICS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84925884421     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660675     Document Type: Article

References (109)

1. INTERNATIONAL DIABETES FEDERATION: DIABETES ATLAS UPDATE 2012. Available from: http://www.idf.org/diabetesatlas/5e/Update2012 (accessed 26/2/2013).
2. WHO. World Health Organisation Fact Sheet No 312. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. (accessed 26/2/2013).
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414: 782-7.
4. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011, 34: 1249-57.
5. Ntzani EE, Kavvoura FK. Genetic risk factors for type 2 diabetes: insights from the emerging genomic evidence. Curr Vasc Pharmacol 2012, 10: 147-55.
6. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352: 837-53.
7. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352: 854-65.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55: 1577-96.
9. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009, 53: 298-304.
10. Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011, 34: 789-94.
11. Hansen M, Sonne DP, Mikkelsen KH, et al. Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. BMJ Open 2012, 2.
12. NCBI. Just the Facts: A Basic Introduction to the Science Underlying NCBI Resources. 2004 Available from: http://www.ncbi.nlm.nih.gov/About/primer/pharm.html. (accessed 26/2/2013).
13. Squassina A, Manchia M, Manolopoulos VG, et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics, 2010, 11: 1149-67.
14. Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet 2001, 29: 306-9.
15. Yesupriya A, Evangelou E, Kavvoura FK, et al. Reporting of human genome epidemiology (HuGE) association studies: an empirical assessment. BMC Med Res Methodol 2008, 8: 31.
16. Evangelou E, Ioannidis JP. Meta-analysis methods for genomewide association studies and beyond. Nat Rev Genet 2013, 14: 379-89.
17. Ntzani EE, Khoury MJ, Ioannidis JP. Combining molecular and genetic data from different sources. IARC Sci Publ 2011, 323-36.
18. Kavvoura FK, Owen KR. Maturity onset diabetes of the young: clinical characteristics, diagnosis and management. Pediatr Endocrinol Rev 2012, 10: 234-42.
19. Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003, 362: 1275-81.
20. Babenko AP, Polak M, Cave H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006, 355: 456-66.
21. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004, 350: 1838-49.
22. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006, 355: 467-77.
23. Yu W, Clyne M, Khoury MJ, et al. Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics 2010, 26: 145-6.
24. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009, 106: 9362-7.
25. Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011, 21: 837-50.
26. Dai XP, Huang Q, Yin JY, et al. KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol 2012, 39: 462-8.
27. Dong M, Gong ZC, Dai XP, et al. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2. Clin Exp Pharmacol Physiol 2011, 38: 824-9.
28. Feng Y, Mao G, Ren X, et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008, 31: 1939-44.
29. Florez JC, Jablonski KA, Kahn SE, et al. Type 2 diabetesassociated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 2007, 56: 531-6.
30. GoDarts U.D.P.S. Group, C. Wellcome Trust Case Control, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011, 43: 117-20.
31. Gong ZC, Huang Q, Dai XP, et al. NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes. Br J Clin Pharmacol 2012, 74: 501-9.
32. He YY, Zhang R, Shao XY, et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol Sin 2008, 29: 983-9.
33. Holstein A, Hahn M, Korner A, et al. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet 2011, 12: 30.
34. Holstein A, Hahn M, Patzer O, et al. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol 2011, 67: 471-6.
35. Huang Q, Yin JY, Dai XP, et al. IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population. Acta Pharmacol Sin 2010, 31: 709-17.
36. Huang Q, Yin JY, Dai XP, et al. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol 2010, 66: 1207-15.
37. Jablonski KA, McAteer JB, deBakker PI, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010, 59: 2672-81.
38. Javorsky M, Klimcakova L, Schroner Z, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med 2012, 23: 245-9.
39. Li Z, Peng X, Wu Y, et al. The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes. Diabetes Obes Metab 2008, 10: 794-802.
40. Majithia AR, Jablonski KA, McAteer JB, et al. Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program. Diabetologia 2011, 54: 2570-4.
41. Makino H, Shimizu I, Murao S, et al. A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at - 420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes. Endocr J 2009, 56: 1049-58.
42. Mathur SK, Rathore R, Chandra S, et al. Primary pioglitazone failure in Asian Indian diabetics is not related to common Pro12Ala polymorph of PPAR-gamma gene. Indian J Physiol Pharmacol 2009, 53: 175-80.
43. Namvaran F, Azarpira N, Rahimi-Moghaddam P, et al. Polymorphism of peroxisome proliferator-activated receptor gamma (PPARgamma) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. Eur J Pharmacol 2011, 671: 1-6.
44. Namvaran F, Rahimi-Moghaddam P, Azarpira N, et al. Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus. Mol Biol Rep 2012, 39: 5511-8.
45. Nikolac N, Simundic AM, Katalinic D, et al. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res 2009, 40: 387-92.
46. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007, 56: 2178-82.
47. Qin W, Zhang R, Hu C, et al. A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. Acta Pharmacol Sin 2010, 31: 450-4.
48. Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009, 10: 1781-7.
49. Sato R, Watanabe H, Genma R, et al. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics 2010, 11: 1743-50.
50. Schroner Z, Dobrikova M, Klimcakova L, et al. Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med Sci Monit 2011, 17: CR3926.
51. Schroner Z, Javorsky M, Haluskova J, et al. Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas. Physiol Res 2012, 61: 177-83.
52. Seeringer A, Parmar S, Fischer A, et al. Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics. Diabetes Obes Metab 2010, 12: 1106-12.
53. Sesti G, Laratta E, Cardellini M, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91: 2334-9.
54. Sesti G, Marini MA, Cardellini M, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004, 27: 1394-8.
55. Sheng FF, Dai XP, Qu J, et al. NAMPT-3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus. Clin Exp Pharmacol Physiol 2011, 38: 550-4.
56. Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007, 52: 117-22.
57. Surendiran A, Pradhan SC, Agrawal A, et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol 2011, 67: 797-801.
58. Suzuki K, Yanagawa T, Shibasaki T, et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006, 72: 148-54.
59. Tkac I, Klimcakova L, Javorsky M, et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab 2013, 15: 189-91.
60. van Leeuwen N, Nijpels G, Becker ML, et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 2012, 55: 1971-7.
61. Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002, 302: 510-5.
62. Wang G, Wang X, Zhang Q, et al. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract 2007, 61: 552-7.
63. Wang S, Se YM, Liu ZQ, et al. Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes. Pharmazie 2012, 67: 74-9.
64. Yu M, Xu XJ, Yin JY, et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 2010, 87: 330-5.
65. Yu W, Hu C, Zhang R, et al. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 2011, 89: 437-42.
66. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995, 268: 423-6.
67. Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002, 12: 101-9.
68. Becker ML, Visser LE, Trienekens PH, et al. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008, 83: 288-92.
69. Zhou K, Donnelly L, Burch L, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2010, 87: 52-6.
70. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003, 52: 568-72.
71. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316: 1336-41.
72. Florez JC, Burtt N, deBakker PI, et al, Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004, 53: 1360-8.
73. Hamming KS, Soliman D, Matemisz LC, et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 2009, 58: 2419-24.
74. Zhang H, Liu X, Kuang H, et al. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract 2007, 77: 58-61.
75. Huang C, Florez JC. Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med 2011, 3: 76.
76. Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012, 44: 981-990.
77. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007, 117: 2155-63.
78. Schroner Z, Javorsky M, Tkacova R, et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13: 89-91.
79. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333: 550-4.
80. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979, 16: 195-202.
81. (NICE), N.I.f.H.a.C.E. The management of type 2 diabetes, NICE clinical guideline 87 (update of NICE clinical guideline 66). May 2009 Available from: http://www.nice.org.uk/nicemedia/live/12165/44322/44322.pdf. (accessed 26/2/2013).
82. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108: 1167-74.
83. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010, 11: 554-65.
84. Becker ML, Visser LE, vanSchaik RH, et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009, 9: 242-7.
85. Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009, 58: 1434-9.
86. Becker ML, Aarnoudse AJ, Newton-Cheh C, et al. Common variation in the NOS1AP gene is associated with reduced glucoselowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet Genomics 2008, 18: 591-7.
87. Becker ML, Visser LE, vanSchaik RH, et al. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010, 20: 38-44.
88. Choi JH, Yee SW, Ramirez AH, et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011, 90: 674-84.
89. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005, 22: 255-9.
90. Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005, 28: 2093-9.
91. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351: 1106-18.
92. Nissen SE, Wolski K. Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170: 1191-1201.
93. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34: 916-22.
94. Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003, 26: 825-31.
95. Chang TJ, Liu PH, Liang YC, et al. Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes. Pharmacogenet Genomics 2011, 21: 829-36.
96. Hsieh MC, Lin KD, Tien KJ, et al. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 2010, 59: 1139-44.
97. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50: 2094-9.
98. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368: 1696-705.
99. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13: 7-18.
100. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alphaglucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006, CD005061.
101. Fonseca VA, HandelsmanY, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 2010, 12: 384-92.
102. Vinik AI, Cincotta AH, Scranton RE, et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract 2012, 18: 931-43.
103. Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012, 2.
104. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009, 461: 747-53.
105. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008, 37: 120-32.
106. Hirsch IB, Amiel SA, Blumer IR, et al. Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers. Diabetes Technol Ther 2012, 14: 973-83, quiz 983.
107. Ntzani EE, Liberopoulos G, Manolio TA, et al. Consistency of genome-wide associations across major ancestral groups. Hum Genet 2012, 131: 1057-71.
108. Pan Z, Trikalinos TA, Kavvoura FK, et al. Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2005, 2: e334.
109. DIRECT. DIabetes REsearCh on patient straTification (DIRECT)., Available from: http://www.direct-diabetes.org. (accessed 26/2/2013).